2nd Quarter - Report
VENN STRATEGIES for BIOMARIN PHARMACEUTICAL, INC.
Firm
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Tax policy affecting bio-pharmaceutical companies
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BEATY New | staff for Sen. Mark Warner (D-VA) |
| TIM CAREY | Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA |
| JESSICA LAYSON DAVIS | Legislative Director for Rep. Austin Scott (R-GA) |
| ELIZABETH LEE | Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin |
| STEPHANIE SILVERMAN | — |
Health Issues HCR
Orphan drugs and rare diseases, matters related to drug reimbursement policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BEATY New | staff for Sen. Mark Warner (D-VA) |
| TIM CAREY | Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA |
| JESSICA LAYSON DAVIS | Legislative Director for Rep. Austin Scott (R-GA) |
| ELIZABETH LEE | Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin |
| STEPHANIE SILVERMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.